CN1545521A - 作为VEGF受体Flt-1拮抗剂的肽 - Google Patents

作为VEGF受体Flt-1拮抗剂的肽 Download PDF

Info

Publication number
CN1545521A
CN1545521A CNA018236154A CN01823615A CN1545521A CN 1545521 A CN1545521 A CN 1545521A CN A018236154 A CNA018236154 A CN A018236154A CN 01823615 A CN01823615 A CN 01823615A CN 1545521 A CN1545521 A CN 1545521A
Authority
CN
China
Prior art keywords
antagonist
peptide
vegf receptor
polypeptides
receptor flt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA018236154A
Other languages
English (en)
Other versions
CN1332978C (zh
Inventor
寿成超
雷和田
安平
吴健
孟麟
刘晓颖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Inst Of Tumor Prevention & Cure
Beijing Institute for Cancer Research
Original Assignee
Beijing Inst Of Tumor Prevention & Cure
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Inst Of Tumor Prevention & Cure filed Critical Beijing Inst Of Tumor Prevention & Cure
Publication of CN1545521A publication Critical patent/CN1545521A/zh
Application granted granted Critical
Publication of CN1332978C publication Critical patent/CN1332978C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了含一个或多个相同或不同的式A－W－H－X1－D－X2－X3－X4－W－W－X5－X6－X7－X8－B(式中各符号的意义见说明书)氨基酸序列的多肽或其药物可接受的盐和含有所述多肽用于治疗血管生成性疾病如实体肿瘤的药物组合物。本发明还涉及编码上述多肽的多核苷酸，以及其基因治疗应用。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CNB018236154A 2001-09-12 2001-09-12 作为VEGF受体Flt－1拮抗剂的肽 Expired - Lifetime CN1332978C (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2001/001393 WO2003022874A1 (en) 2001-09-12 2001-09-12 Antagonist peptides to vegr receptor flt-1

Publications (2)

Publication Number Publication Date
CN1545521A true CN1545521A (zh) 2004-11-10
CN1332978C CN1332978C (zh) 2007-08-22

Family

ID=4574858

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018236154A Expired - Lifetime CN1332978C (zh) 2001-09-12 2001-09-12 作为VEGF受体Flt－1拮抗剂的肽

Country Status (3)

Country Link
US (1) US7250395B2 (zh)
CN (1) CN1332978C (zh)
WO (1) WO2003022874A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111326A1 (en) * 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
JP2009114066A (ja) * 2006-02-24 2009-05-28 International Medical Center Of Japan 機能性分子が導入された有機磁性ナノ複合体
CN108623694B (zh) * 2017-03-24 2021-09-17 北京市肿瘤防治研究所 血管内皮细胞生长因子受体拮抗肽f56的衍生物及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
US20050019826A1 (en) 2000-03-31 2005-01-27 Roselyne Tournaire Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof

Also Published As

Publication number Publication date
WO2003022874A1 (en) 2003-03-20
CN1332978C (zh) 2007-08-22
US20050154187A1 (en) 2005-07-14
US7250395B2 (en) 2007-07-31

Similar Documents

Publication Publication Date Title
GEP20074267B (en) Receptor nucleic acids and polypeptides
EP2650303A1 (en) Methods and compositions for the treatment of heart failure and other disorders
SG145712A1 (en) Crystalline tumor necrosis factor receptor 2 polypeptides
WO2003048164A3 (en) Adenosine a2a receptor antagonists
EA020466B1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
CA2257133A1 (en) Human dnase i hyperactive variants
CA2184908A1 (en) Human osteoclast-derived cathepsin
JO2371B1 (en) 4-phenyl-pyridine derivatives
AU2304300A (en) Indole derivatives and their use as mcp-1 receptor antagonists
WO2001032926A3 (en) Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
TW200902067A (en) Inhibitors of IAP
CN104768948B (zh) 作为选择性parp-1抑制剂的4-甲酰氨基-异二氢吲哚酮衍生物
WO2002087507A3 (en) Breast cancer-associated genes and uses thereof
CA2468649A1 (en) Adenosine a2a receptor antagonists
EP1217067A2 (en) Connective tissue growth factor-2
SE0104331D0 (sv) Novel compounds
WO2002062819A3 (en) Backbone cyclized radiolabelled somatostatin analogs
WO2003008446A1 (fr) Polypeptides se rapportant au transfert de signaux de recepteur de produits terminaux a glycation avancee
CN1545521A (zh) 作为VEGF受体Flt-1拮抗剂的肽
WO2003087338A3 (en) Her-2 receptor tyrosine kinase molecules and uses thereof
WO2001068120A3 (en) Uses of bombesin receptor 3
CN115768765A (zh) 用于治疗遗传疾病的方法和化合物
WO2005019259A3 (en) Variants of interleukin-1 receptor antagonist: compositions and uses thereof
WO2004085461A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
WO2001049711A3 (en) Nucleic acids encoding (poly)peptides having chips activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20070822

CX01 Expiry of patent term